Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Inflammatory Bowel Diseases

  Free Subscription

Articles published in PLoS One

Retrieve available abstracts of 113 articles:
HTML format

Single Articles

    January 2022
  1. PARK J, Yoon H, Shin CM, Park YS, et al
    Clinical factors to predict flare-up in patients with inflammatory bowel disease during international air travel: A prospective study.
    PLoS One. 2022;17:e0262571.
    PubMed     Abstract available

  2. BAKER KA, Miller TD, Marino FE, Hartmann TE, et al
    The exercise-induced inflammatory response in inflammatory bowel disease: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0262534.
    PubMed     Abstract available

  3. LAI HC, Chou JW, Wu YH, Huang PJ, et al
    ABO blood type and clinical characteristics of patients with ulcerative colitis: A hospital-based study in central Taiwan.
    PLoS One. 2022;17:e0260018.
    PubMed     Abstract available

  4. XU F, Wheaton AG, Liu Y, Greenlund KJ, et al
    Major ambulatory surgery among US adults with inflammatory bowel disease, 2017.
    PLoS One. 2022;17:e0264372.
    PubMed     Abstract available

  5. GARDINER LJ, Carrieri AP, Bingham K, Macluskie G, et al
    Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease.
    PLoS One. 2022;17:e0263248.
    PubMed     Abstract available

  6. TONG G, Qian H, Li D, Li J, et al
    Establishment and evaluation of a specific antibiotic-induced inflammatory bowel disease model in rats.
    PLoS One. 2022;17:e0264194.
    PubMed     Abstract available

  7. SAETERSTAD S, Ostvik AE, Royset ES, Bakke I, et al
    Profound gene expression changes in the epithelial monolayer of active ulcerative colitis and Crohn's disease.
    PLoS One. 2022;17:e0265189.
    PubMed     Abstract available

  8. YAO J, Fekadu G, Jiang X, You JHS, et al
    Telemonitoring for patients with inflammatory bowel disease amid the COVID-19 pandemic-A cost-effectiveness analysis.
    PLoS One. 2022;17:e0266464.
    PubMed     Abstract available

  9. LEE SH, Veeriah V, Levine F
    A potent HNF4alpha agonist reveals that HNF4alpha controls genes important in inflammatory bowel disease and Paneth cells.
    PLoS One. 2022;17:e0266066.
    PubMed     Abstract available

  10. NGUYEN TB, Do DN, Nguyen TTP, Nguyen TL, et al
    Immune-related biomarkers shared by inflammatory bowel disease and liver cancer.
    PLoS One. 2022;17:e0267358.
    PubMed     Abstract available

  11. WAKAI M, Hayashi R, Ueno Y, Onishi K, et al
    Promoting mechanism of serum amyloid a family expression in mouse intestinal epithelial cells.
    PLoS One. 2022;17:e0264836.
    PubMed     Abstract available

  12. SHEU NW, Huang SH, Wu DC, Kao JY, et al
    Effects of Helicobacter pylori treatment on the incidences of autoimmune diseases and inflammatory bowel disease in patients with diabetes mellitus.
    PLoS One. 2022;17:e0265323.
    PubMed     Abstract available

  13. WEDENOJA S, Saarikivi A, Malkonen J, Leskinen S, et al
    Fecal microbiota in congenital chloride diarrhea and inflammatory bowel disease.
    PLoS One. 2022;17:e0269561.
    PubMed     Abstract available

  14. HIGUCHI N, Hiraga H, Sasaki Y, Hiraga N, et al
    Automated evaluation of colon capsule endoscopic severity of ulcerative colitis using ResNet50.
    PLoS One. 2022;17:e0269728.
    PubMed     Abstract available

  15. WANG J, Kou F, Han X, Shi L, et al
    Inflammatory bowel disease and risk of idiopathic pulmonary fibrosis: A protocol for systematic review and meta-analysis.
    PLoS One. 2022;17:e0270297.
    PubMed     Abstract available

  16. OZAKA S, Sonoda A, Ariki S, Minata M, et al
    Saireito, a Japanese herbal medicine, alleviates leaky gut associated with antibiotic-induced dysbiosis in mice.
    PLoS One. 2022;17:e0269698.
    PubMed     Abstract available

    January 2021
  17. KERN I, Schoffer O, Kiess W, Henker J, et al
    Incidence trends of pediatric onset inflammatory bowel disease in the years 2000-2009 in Saxony, Germany-first results of the Saxon Pediatric IBD Registry.
    PLoS One. 2021;16:e0243774.
    PubMed     Abstract available

  18. KONSTANTINIDIS AO, Adamama-Moraitou KK, Pardali D, Dovas CI, et al
    Colonic mucosal and cytobrush sample cytokine mRNA expression in canine inflammatory bowel disease and their correlation with disease activity, endoscopic and histopathologic score.
    PLoS One. 2021;16:e0245713.
    PubMed     Abstract available

  19. NAFTALI T, Bar-Lev Schleider L, Scklerovsky Benjaminov F, Konikoff FM, et al
    Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial.
    PLoS One. 2021;16:e0246871.
    PubMed     Abstract available

  20. REVILLA L, Mayorgas A, Corraliza AM, Masamunt MC, et al
    Multi-omic modelling of inflammatory bowel disease with regularized canonical correlation analysis.
    PLoS One. 2021;16:e0246367.
    PubMed     Abstract available

  21. DING ZH, Xu XP, Wang TR, Liang X, et al
    The prevalence of Helicobacter pylori infection in inflammatory bowel disease in China: A case-control study.
    PLoS One. 2021;16:e0248427.
    PubMed     Abstract available

  22. RANA T, Korolkova OY, Rachakonda G, Williams AD, et al
    Linking bacterial enterotoxins and alpha defensin 5 expansion in the Crohn's colitis: A new insight into the etiopathogenetic and differentiation triggers driving colonic inflammatory bowel disease.
    PLoS One. 2021;16:e0246393.
    PubMed     Abstract available

  23. ARKTEG CB, Wergeland Sorbye S, Buhl Riis L, Dalen SM, et al
    Real-life evaluation of histologic scores for Ulcerative Colitis in remission.
    PLoS One. 2021;16:e0248224.
    PubMed     Abstract available

  24. TAMAN H, Fenton CG, Anderssen E, Florholmen J, et al
    DNA hypo-methylation facilitates anti-inflammatory responses in severe ulcerative colitis.
    PLoS One. 2021;16:e0248905.
    PubMed     Abstract available

  25. FURUSE M, Hosomi S, Nishida Y, Itani S, et al
    The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients.
    PLoS One. 2021;16:e0250597.
    PubMed     Abstract available

  26. XU F, Park S, Liu Y, Greenlund KJ, et al
    Dietary intake patterns among adults with inflammatory bowel disease in the United States, 2015.
    PLoS One. 2021;16:e0250441.
    PubMed     Abstract available

  27. ISHIDA N, Higuchi T, Miyazu T, Tamura S, et al
    Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease.
    PLoS One. 2021;16:e0250658.
    PubMed     Abstract available

  28. BUSINGYE D, Pollack A, Chidwick K
    Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study.
    PLoS One. 2021;16:e0252458.
    PubMed     Abstract available

  29. TREFZER R, Elpeleg O, Gabrusskaya T, Stepensky P, et al
    Characterization of a L136P mutation in Formin-like 2 (FMNL2) from a patient with chronic inflammatory bowel disease.
    PLoS One. 2021;16:e0252428.
    PubMed     Abstract available

  30. YEN HH, Su PY, Huang SP, Wu L, et al
    Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study.
    PLoS One. 2021;16:e0252286.
    PubMed     Abstract available

  31. SMITH SCL, Banbury C, Zardo D, Cannatelli R, et al
    Raman spectroscopy accurately differentiates mucosal healing from non-healing and biochemical changes following biological therapy in inflammatory bowel disease.
    PLoS One. 2021;16:e0252210.
    PubMed     Abstract available

  32. CAPITANO ML, Jaiswal A, Broxmeyer HE, Pride Y, et al
    A humanized monoclonal antibody against the endothelial chemokine CCL21 for the diagnosis and treatment of inflammatory bowel disease.
    PLoS One. 2021;16:e0252805.
    PubMed     Abstract available

  33. KATO M, Sugimoto K, Ikeya K, Takano R, et al
    Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease.
    PLoS One. 2021;16:e0254548.
    PubMed     Abstract available

  34. ORFEI M, Gasparetto M, Hensel KO, Zellweger F, et al
    Guidance on the interpretation of faecal calprotectin levels in children.
    PLoS One. 2021;16:e0246091.
    PubMed     Abstract available

  35. MADARAME A, Fukuzawa M, Yamauchi Y, Kono S, et al
    Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase.
    PLoS One. 2021;16:e0255620.
    PubMed     Abstract available

  36. LEE JM, Jang JH, Ryu JH, Yoo J, et al
    A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease.
    PLoS One. 2021;16:e0255974.
    PubMed     Abstract available

  37. GAN RW, Sun D, Tatro AR, Cohen-Mekelburg S, et al
    Replicating prediction algorithms for hospitalization and corticosteroid use in patients with inflammatory bowel disease.
    PLoS One. 2021;16:e0257520.
    PubMed     Abstract available

  38. ZHANG L, Wu YB, Dai YK, Liu Q, et al
    Efficacy and safety of Qingre-Chushi therapies in active ulcerative colitis: A network meta-analysis.
    PLoS One. 2021;16:e0257599.
    PubMed     Abstract available

  39. KARMI N, Bangma A, Spekhorst LM, van Dullemen HM, et al
    Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFalpha therapy in inflammatory bowel disease.
    PLoS One. 2021;16:e0256860.
    PubMed     Abstract available

  40. AL-SADI R, Engers J, Haque M, King S, et al
    Matrix Metalloproteinase-9 (MMP-9) induced disruption of intestinal epithelial tight junction barrier is mediated by NF-kappaB activation.
    PLoS One. 2021;16:e0249544.
    PubMed     Abstract available

  41. CREEMERS RH, Rezazadeh Ardabili A, Jonkers DM, Leers MPG, et al
    Severe COVID-19 in inflammatory bowel disease patients in a population-based setting.
    PLoS One. 2021;16:e0258271.
    PubMed     Abstract available

  42. TAO F, Xing X, Wu J, Jiang R, et al
    Enteral nutrition modulation with n-3 PUFAs directs microbiome and lipid metabolism in mice.
    PLoS One. 2021;16:e0248482.
    PubMed     Abstract available

  43. MEI Z, Feng Q, Du P, Li B, et al
    Surgical treatment for cryptoglandular and Crohn's perianal fistulas: Protocol of an umbrella review.
    PLoS One. 2021;16:e0251460.
    PubMed     Abstract available

  44. MORAN MM, Wessman P, Rolfson O, Bohl DD, et al
    The risk of revision following total hip arthroplasty in patients with inflammatory bowel disease, a registry based study.
    PLoS One. 2021;16:e0257310.
    PubMed     Abstract available

  45. BIN MASUD S, Jenkins C, Hussey E, Elkin-Frankston S, et al
    Utilizing machine learning with knockoff filtering to extract significant metabolites in Crohn's disease with a publicly available untargeted metabolomics dataset.
    PLoS One. 2021;16:e0255240.
    PubMed     Abstract available

  46. MIYAZAKI C, Katsumasa N, Huang KC, Liu YF, et al
    Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan.
    PLoS One. 2021;16:e0254807.
    PubMed     Abstract available

  47. WILSON PA, Santos Franco S, He L, Galwey NW, et al
    Transcriptomic effects of rs4845604, an IBD and allergy-associated RORC variant, in stimulated ex vivo CD4+ T cells.
    PLoS One. 2021;16:e0258316.
    PubMed     Abstract available

  48. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
    Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease.
    PLoS One. 2021;16:e0249809.
    PubMed     Abstract available

  49. PARK HT, Park WB, Kim S, Lim JS, et al
    Revealing immune responses in the Mycobacterium avium subsp. paratuberculosis-infected THP-1 cells using single cell RNA-sequencing.
    PLoS One. 2021;16:e0254194.
    PubMed     Abstract available

  50. WANG J, Bleich RM, Zarmer S, Zhang S, et al
    Long-read sequencing to interrogate strain-level variation among adherent-invasive Escherichia coli isolated from human intestinal tissue.
    PLoS One. 2021;16:e0259141.
    PubMed     Abstract available

  51. MORIKUBO H, Kobayashi T, Fukuda T, Nagahama T, et al
    Development of algorithms for identifying patients with Crohn's disease in the Japanese health insurance claims database.
    PLoS One. 2021;16:e0258537.
    PubMed     Abstract available

  52. IRAK K, Bayram M, Cifci S, Sener G, et al
    Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn's disease.
    PLoS One. 2021;16:e0260034.
    PubMed     Abstract available

  53. KHAN IA, Nayak B, Markandey M, Bajaj A, et al
    Differential prevalence of pathobionts and host gene polymorphisms in chronic inflammatory intestinal diseases: Crohn's disease and intestinal tuberculosis.
    PLoS One. 2021;16:e0256098.
    PubMed     Abstract available

    January 2020
  54. ARMUZZI A, DiBonaventura MD, Tarallo M, Lucas J, et al
    Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe.
    PLoS One. 2020;15:e0227914.
    PubMed     Abstract available

  55. CIAPPONI A, Virgilio SA, Berrueta M, Soto NC, et al
    Epidemiology of inflammatory bowel disease in Mexico and Colombia: Analysis of health databases, mathematical modelling and a case-series study.
    PLoS One. 2020;15:e0228256.
    PubMed     Abstract available

  56. JODELEIT H, Milchram L, Soldo R, Beikircher G, et al
    Autoantibodies as diagnostic markers and potential drivers of inflammation in ulcerative colitis.
    PLoS One. 2020;15:e0228615.
    PubMed     Abstract available

  57. DANG X, Xu M, Liu D, Zhou D, et al
    Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0228846.
    PubMed     Abstract available

  58. YU TB, Dodd S, Yu LG, Subramanian S, et al
    Serum galectins as potential biomarkers of inflammatory bowel diseases.
    PLoS One. 2020;15:e0227306.
    PubMed     Abstract available

  59. LIM WW, Ng B, Widjaja A, Xie C, et al
    Transgenic interleukin 11 expression causes cross-tissue fibro-inflammation and an inflammatory bowel phenotype in mice.
    PLoS One. 2020;15:e0227505.
    PubMed     Abstract available

  60. KUBESCH A, Boulahrout P, Filmann N, Blumenstein I, et al
    Real-world data about emotional stress, disability and need for social care in a German IBD patient cohort.
    PLoS One. 2020;15:e0227309.
    PubMed     Abstract available

  61. HAN MK, Anderson R, Viennois E, Merlin D, et al
    Examination of food consumption in United States adults and the prevalence of inflammatory bowel disease using National Health Interview Survey 2015.
    PLoS One. 2020;15:e0232157.
    PubMed     Abstract available

  62. YAMAMOTO-FURUSHO JK, Mendieta-Escalante EA
    Diagnostic utility of the neutrophil-platelet ratio as a novel marker of activity in patients with Ulcerative Colitis.
    PLoS One. 2020;15:e0231988.
    PubMed     Abstract available

  63. HAZLEWOOD GS, Pokharel G, Deardon R, Marshall DA, et al
    Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment.
    PLoS One. 2020;15:e0227635.
    PubMed     Abstract available

  64. BROKERHOF IM, Ybema JF, Bal PM
    Illness narratives and chronic patients' sustainable employability: The impact of positive work stories.
    PLoS One. 2020;15:e0228581.
    PubMed     Abstract available

  65. KUNOVSZKI P, Milassin A, Gimesi-Orszagh J, Takacs P, et al
    Epidemiology, mortality and prevalence of colorectal cancer in ulcerative colitis patients between 2010-2016 in Hungary - a population-based study.
    PLoS One. 2020;15:e0233238.
    PubMed     Abstract available

  66. MAVROPOULOU E, Mechie NC, Knoop R, Petzold G, et al
    Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study.
    PLoS One. 2020;15:e0233811.
    PubMed     Abstract available

  67. BURISCH J, Eigner W, Schreiber S, Aletaha D, et al
    Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0233781.
    PubMed     Abstract available

  68. ARAKI M, Shinzaki S, Yamada T, Arimitsu S, et al
    Psychologic stress and disease activity in patients with inflammatory bowel disease: A multicenter cross-sectional study.
    PLoS One. 2020;15:e0233365.
    PubMed     Abstract available

  69. PARK J, Yoon H, Shin CM, Park YS, et al
    Higher levels of disease-related knowledge reduce medical acceleration in patients with inflammatory bowel disease.
    PLoS One. 2020;15:e0233654.
    PubMed     Abstract available

  70. SCOVILLE EA, Tindle HA, Wells QS, Peyton SC, et al
    Precision nicotine metabolism-informed care for smoking cessation in Crohn's disease: A pilot study.
    PLoS One. 2020;15:e0230656.
    PubMed     Abstract available

  71. WANG J, Ortiz C, Fontenot L, Xie Y, et al
    High circulating elafin levels are associated with Crohn's disease-associated intestinal strictures.
    PLoS One. 2020;15:e0231796.
    PubMed     Abstract available

  72. ZHOU M, Xu R, Kaelber DC, Gurney ME, et al
    Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis.
    PLoS One. 2020;15:e0229819.
    PubMed     Abstract available

  73. KANG EA, Chun J, Im JP, Lee HJ, et al
    Anemia is associated with the risk of Crohn's disease, not ulcerative colitis: A nationwide population-based cohort study.
    PLoS One. 2020;15:e0238244.
    PubMed     Abstract available

  74. WIDBOM L, Schneede J, Midttun O, Ueland PM, et al
    Elevated plasma cotinine is associated with an increased risk of developing IBD, especially among users of combusted tobacco.
    PLoS One. 2020;15:e0235536.
    PubMed     Abstract available

  75. HALE LP
    Deficiency of activation-induced cytidine deaminase in a murine model of ulcerative colitis.
    PLoS One. 2020;15:e0239295.
    PubMed     Abstract available

  76. TABORELLI M, Sozzi M, Del Zotto S, Toffolutti F, et al
    Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy.
    PLoS One. 2020;15:e0235142.
    PubMed     Abstract available

  77. PARK A, Kim S, Jung IH, Byun JH, et al
    An immune therapy model for effective treatment on inflammatory bowel disease.
    PLoS One. 2020;15:e0238918.
    PubMed     Abstract available

  78. CALDEIRA LF, Borba HH, Tonin FS, Wiens A, et al
    Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0238910.
    PubMed     Abstract available

  79. SCHNITZLER F, Friedrich M, Angelberger M, Diegelmann J, et al
    Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgery.
    PLoS One. 2020;15:e0236421.
    PubMed     Abstract available

  80. CAI B, Zhou MH, Huang HL, Zhou AC, et al
    Protective effects of citrulline supplementation in ulcerative colitis rats.
    PLoS One. 2020;15:e0240883.
    PubMed     Abstract available

  81. ALLAIS L, Verschuere S, Maes T, De Smet R, et al
    Translational research into the effects of cigarette smoke on inflammatory mediators and epithelial TRPV1 in Crohn's disease.
    PLoS One. 2020;15:e0236657.
    PubMed     Abstract available

  82. NISHIDA Y, Hosomi S, Yamagami H, Fujimoto K, et al
    Novel prognostic biomarkers of pouchitis after ileal pouch-anal anastomosis for ulcerative colitis: Neutrophil-to-lymphocyte ratio.
    PLoS One. 2020;15:e0241322.
    PubMed     Abstract available

  83. UCHIYAMA K, Takami S, Suzuki H, Umeki K, et al
    Efficacy and safety of short-term therapy with indigo naturalis for ulcerative colitis: An investigator-initiated multicenter double-blind clinical trial.
    PLoS One. 2020;15:e0241337.
    PubMed     Abstract available

  84. HOFFMANN P, Behnisch R, Gsenger J, Schnitzler P, et al
    Hepatitis E seroprevalence in a German cohort of patients with inflammatory bowel diseases.
    PLoS One. 2020;15:e0239825.
    PubMed     Abstract available

  85. LIMSRIVILAI J, Lee CK, Prueksapanich P, Harinwan K, et al
    Validation of models using basic parameters to differentiate intestinal tuberculosis from Crohn's disease: A multicenter study from Asia.
    PLoS One. 2020;15:e0242879.
    PubMed     Abstract available

  86. DOMENIS R, Marino M, Cifu A, Scardino G, et al
    Circulating exosomes express alpha4beta7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
    PLoS One. 2020;15:e0242342.
    PubMed     Abstract available

  87. LI LN, Liu Y, Zhang HC, Wu T, et al
    Helicobacter pylori infection reduces TAMs infiltration in a mouse model of AOM/DSS induced colitis-associated cancer.
    PLoS One. 2020;15:e0241840.
    PubMed     Abstract available

    January 2019
  88. THOMAS T, Chandan JS, Li VSW, Lai CY, et al
    Global smoking trends in inflammatory bowel disease: A systematic review of inception cohorts.
    PLoS One. 2019;14:e0221961.
    PubMed     Abstract available

  89. DEURING JJ, Li M, Cao W, Chen S, et al
    Pregnane X receptor activation constrains mucosal NF-kappaB activity in active inflammatory bowel disease.
    PLoS One. 2019;14:e0221924.
    PubMed     Abstract available

  90. PALMER NP, Silvester JA, Lee JJ, Beam AL, et al
    Concordance between gene expression in peripheral whole blood and colonic tissue in children with inflammatory bowel disease.
    PLoS One. 2019;14:e0222952.
    PubMed     Abstract available

  91. BATHE AL, Mavropoulou E, Mechie NC, Petzold G, et al
    Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis.
    PLoS One. 2019;14:e0223893.
    PubMed     Abstract available

  92. COLLIJ V, Imhann F, Vich Vila A, Fu J, et al
    SLC39A8 missense variant is associated with Crohn's disease but does not have a major impact on gut microbiome composition in healthy subjects.
    PLoS One. 2019;14:e0211328.
    PubMed     Abstract available

  93. VON MARTELS JZH, Bourgonje AR, Harmsen HJM, Faber KN, et al
    Assessing intestinal permeability in Crohn's disease patients using orally administered 52Cr-EDTA.
    PLoS One. 2019;14:e0211973.
    PubMed     Abstract available

  94. MATTHEWS SM, Eshelman MA, Berg AS, Koltun WA, et al
    The Crohn's disease associated SNP rs6651252 impacts MYC gene expression in human colonic epithelial cells.
    PLoS One. 2019;14:e0212850.
    PubMed     Abstract available

  95. SAGAMI S, Kobayashi T, Kikkawa N, Umeda S, et al
    Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease.
    PLoS One. 2019;14:e0212404.
    PubMed     Abstract available

  96. GOLL R, Heitmann R, Moe OK, Carlsen K, et al
    Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis.
    PLoS One. 2019;14:e0224895.
    PubMed     Abstract available

  97. ATHERLY T, Rossi G, White R, Seo YJ, et al
    Glucocorticoid and dietary effects on mucosal microbiota in canine inflammatory bowel disease.
    PLoS One. 2019;14:e0226780.
    PubMed     Abstract available

  98. HAISMA SM, Galaurchi A, Almahwzi S, Adekanmi Balogun JA, et al
    Head-to-head comparison of three stool calprotectin tests for home use.
    PLoS One. 2019;14:e0214751.
    PubMed     Abstract available

  99. COLONETTI K, Bento Dos Santos B, Nalin T, Moura de Souza CF, et al
    Hepatic glycogen storage diseases are associated to microbial dysbiosis.
    PLoS One. 2019;14:e0214582.
    PubMed     Abstract available

  100. LI E, Zhang Y, Tian X, Wang X, et al
    Influence of Crohn's disease related polymorphisms in innate immune function on ileal microbiome.
    PLoS One. 2019;14:e0213108.
    PubMed     Abstract available

  101. ROBINSON SC, Chaudhary R, Jimenez-Saiz R, Rayner LGA, et al
    Kaiso-induced intestinal inflammation is preceded by diminished E-cadherin expression and intestinal integrity.
    PLoS One. 2019;14:e0217220.
    PubMed     Abstract available

  102. KONDO K, Ohfuji S, Watanabe K, Yamagami H, et al
    The association between environmental factors and the development of Crohn's disease with focusing on passive smoking: A multicenter case-control study in Japan.
    PLoS One. 2019;14:e0216429.
    PubMed     Abstract available

  103. SAMARANI S, Mack DR, Bernstein CN, Iannello A, et al
    Activating Killer-cell Immunoglobulin-like Receptor genes confer risk for Crohn's disease in children and adults of the Western European descent: Findings based on case-control studies.
    PLoS One. 2019;14:e0217767.
    PubMed     Abstract available

  104. BON L, Scharl S, Vavricka S, Rogler G, et al
    Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study.
    PLoS One. 2019;14:e0215738.
    PubMed     Abstract available

  105. TALPIN A, Kattah MG, Advincula R, Fadrosh D, et al
    A20 in dendritic cells restrains intestinal anti-bacterial peptide expression and preserves commensal homeostasis.
    PLoS One. 2019;14:e0218999.
    PubMed     Abstract available

  106. MARKOTA A, Metzger R, Heiseke AF, Jandl L, et al
    Comparison of iron-reduced and iron-supplemented semisynthetic diets in T cell transfer colitis.
    PLoS One. 2019;14:e0218332.
    PubMed     Abstract available

  107. HOLOTA Y, Dovbynchuk T, Kaji I, Vareniuk I, et al
    The long-term consequences of antibiotic therapy: Role of colonic short-chain fatty acids (SCFA) system and intestinal barrier integrity.
    PLoS One. 2019;14:e0220642.
    PubMed     Abstract available

  108. ADLER J, Jary HK, Eder SJ, Dong S, et al
    Identifying perianal fistula complications in pediatric patients with Crohn's disease using administrative claims.
    PLoS One. 2019;14:e0219893.
    PubMed     Abstract available

  109. BOTTOMS L, Leighton D, Carpenter R, Anderson S, et al
    Affective and enjoyment responses to 12 weeks of high intensity interval training and moderate continuous training in adults with Crohn's disease.
    PLoS One. 2019;14:e0222060.
    PubMed     Abstract available

  110. WOLOSZYNEK S, Mell JC, Zhao Z, Simpson G, et al
    Exploring thematic structure and predicted functionality of 16S rRNA amplicon data.
    PLoS One. 2019;14:e0219235.
    PubMed     Abstract available

  111. ABBAS M, Matta J, Le T, Bensmail H, et al
    Biomarker discovery in inflammatory bowel diseases using network-based feature selection.
    PLoS One. 2019;14:e0225382.
    PubMed     Abstract available

  112. KUBOTA M, Kakimoto K, Nakagawa T, Koubayashi E, et al
    Autophagy deficiency exacerbates colitis through excessive oxidative stress and MAPK signaling pathway activation.
    PLoS One. 2019;14:e0225066.
    PubMed     Abstract available

  113. COOPE A, Pascoal LB, Botezelli JD, da Silva FAR, et al
    ER stress activation in the intestinal mucosa but not in mesenteric adipose tissue is associated with inflammation in Crohn's disease patients.
    PLoS One. 2019;14:e0223105.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.